🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06245954
Recruiting Not applicable

The Role of Standardized Training in the Diagnosis of Interstitial Lung Disease by Transbronchial Lung Cryobiopsy

NCT06245954 · tracked via the Priya Life Science China tracker
Sponsor
China-Japan Friendship Hospital
Phase
Not applicable
Started
2024-03-01
Last updated
2025-02-10

Condition(s) studied

Transbronchial Lung Cryobiopsy

Investigational drug(s) / intervention(s)

simulated trainingtraditional bedside teaching

simulated training: Simulation training of bronchoscopists by means of simulators and extracorporeal lungs

traditional bedside teaching: TBLC training for bronchoscopists through traditional lectures, hands-on demonstrations

Study summary

The aim of this study was to conduct a prospective randomized controlled trial to design simulator and in vitro lung standardized training, to perform a learning curve evaluation of transbronchial lung cryobiopsy (TBLC) operating physicians, and to assess the role of standardized training in TBLC.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * suspected ILD. * ≤3 months since HRCT * Forced vital capacity (FVC) ≥50% of predicted value * Diffused lung carbon monoxide (DLCO) ≥35% predicted value * Echocardiography ≤ 12 months * Estimated pulmonary artery systolic pressure ≤40 mmHg * Body mass index (BMI) ≤35 kg/m2 * Patient consent for experimentation Exclusion Criteria: * Patients with platelet counts less than 50 × 109/L or prothrombin time international normalized ratio (INR) higher than 1.5 * Patients refused to participate in the experiment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
China-Japan Friendship Hospital Beijing Beijing Municipality Recruiting

More China-Japan Friendship Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06245954 on ClinicalTrials.gov ↗ ← All trials in China